Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Ulrich Reiser

Harald Engelhardt

Matthias Treu

Stephan Karl Zahn

Ulrich Guertler

Flavio Solca

Heinz Stadtmueller

Rudolf Hauptmann

Martin Steegmaier

Andreas Schoop

Walter Spevak

Ulrike Tontsch-Grunt

Christian Smethurst

Jens Juergen Quant

Guido Boehmelt

Davide Gianni

Oliver Kraemer

Andreas Steffen

Thomas Karner

Matthias Grauert

Thorsten K Oost

Georg Dahmann

Matthias Hoffmann

Herbert Nar

Tobias Wunberg

Sandra Handschuh

Cédrickx Godbout

Anke Baum

Juergen Ramharter

Peter Ettmayer

Andreas Mantoulidis

Dirk Kessler

Bodo Betzemeier

Otmar Schaaf

Daniel Kuhn

Dirk Scharn

James Madden

Sebastian Carotta

Peter Sennhenn

Mark Petronczki

Alastair L Parkes

Bojan Bister

Gerd Bader

Lars Herfurth

The present invention relates to heterocyclic compounds of formula (I) capable of activating STING (Stimulator of Interferon Genes).

Heterocyclic compounds capable of activating STING

The present invention encompasses compounds of formula (I) wherein the groups Rto Rand Xto Xhave the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors

6-Alkynyl-pyridine of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. An exemplary compound is 

6-alkyny-pyridine derivatives

6-alkynyl-pyridine derivatives

Disclosed are compounds of general formula (I) wherein the groups Rto Rhave the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

Triazolopyridazine

This invention relates to 6-alkynyl-pyridine of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups Rto Rhave the meanings given in the claims and in the specification.

6-Alkynyl Pyridine

This invention relates to bis-amido pyridines of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups Rto Rhave the meanings given in the claims and in the specification.

Bis-amido pyridines

The present invention encompasses compounds of general formula (I) wherein the groups Rto Rand Ato Ahave the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

Dihydroquinazolinone analogues

6-Alkynylpyridines which are SMAC mimetics and are useful as medicaments for the treatment of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The following compounds are exemplary:

6-alkynylpyridines

The present invention encompasses compounds of general formula (1), wherein Rto Rare defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties. 

Compounds

The present invention encompasses compounds of general formula (1) wherein

The present invention encompasses compounds of general Formula (1) wherein R, R, Q, W, X, Y and Z are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties. 

Substituted indolines as tyrosine kinase inhibitors

The present invention encompasses compounds of general formula (1) wherein R, M, Land Q are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties. 

Chemical compounds

The present invention encompasses compounds of general formula (1), wherein

Pyrimidines as PLK inhibitors

Growing community of inventors

Vienna, Austria

Ulrich Reiser